FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
News|Articles|July 24, 2024
Accelerating Small Molecule Advancements: The Power of Collaboration Between CDMOs and Biotechs (July 2024)
Author(s)Lonza
The increasing number of breakthroughs in small molecule drug development are exciting, but corresponding workflows are complex and require much more tailored approaches to ensure successful upstream and downstream processing, drug approvals and commercialization.
Related to this article
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.
FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.
Science, circularity, regulation, and technology are reshaping how the industry develops packaging for medicines.
Trending on Pharmaceutical Technology
1
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
2
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
3
Nitrosamine Problems and Industry Solutions: PharmTech Explained
4
Sustainability in Healthcare Packaging: The Journey From Yesterday to Tomorrow
5